Skip to main content
. 2021 Apr 28;20:92. doi: 10.1186/s12933-021-01281-y

Fig. 2.

Fig. 2

The choice of glucose lowering agents. Established ASCVD: Prior proven coronary artery disease, cerebrovascular disease or peripheral arterial disease. Risk factors for ASCVD: Older age (male > 50, female > 55) and one or more risk factor(s) for cardiovascular disease - HTN, hyperlipidemia, (current) smoker. HF: Prior clinical or imaging diagnosis of HFrEF. Risk factors for HF: According to TIMI risk-score [47]. CKD: eGFR < 90 ml/min/1.73 m2 and/or UACR ≥ 30 mg/g. Obesity: BMI > 30 kg/m2. ASCVD Atherosclerotic cardiovascular disease, HTN Hypertension, HF Heart failure, HFpEF Heart failure with preserved ejection fraction, HFrEF Heart failure with reduced ejection fraction, CKD Chronic kidney disease, eGFR estimated glomerular filtration rate, UACR Urinary albumin to creatinine ratio, BMI Body mass index, SGLT2i Sodium glucose co-transporter type 2 inhibitor, GLP-1 RA Glucagon-like peptide-1 receptor agonists, DMD Disease/Diabetes modifying drug (either SGLT2i or GLP-1 RA)